Business Description
Tryptamine Therapeutics Ltd
ISIN : AU0000331993
Share Class Description:
TYPTF: Ordinary SharesDescription
Tryptamine Therapeutics Ltd is a clinical-stage biotechnology company focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. The programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy. Its product pipeline includes TRP-8803 (IV-infused psilocin) and TRP-8802 (oral psilocybin).
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.7 | |||||
| Equity-to-Asset | 0.88 | |||||
| Debt-to-Equity | 0.57 | |||||
| Debt-to-EBITDA | -2.45 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 9.44 | |||||
| Beneish M-Score | -3.47 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 28.7 | |||||
| 3-Year EPS without NRI Growth Rate | 9.8 | |||||
| 3-Year FCF Growth Rate | 32.9 | |||||
| 3-Year Book Growth Rate | -41.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 56.57 | |||||
| 9-Day RSI | 54.6 | |||||
| 14-Day RSI | 54.21 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.83 | |||||
| Quick Ratio | 7.83 | |||||
| Cash Ratio | 7.65 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -59.7 | |||||
| Shareholder Yield % | 1.89 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1978.82 | |||||
| Net Margin % | -1693.73 | |||||
| FCF Margin % | -562.57 | |||||
| ROE % | -115.34 | |||||
| ROA % | -80.57 | |||||
| ROIC % | -164.7 | |||||
| ROC (Joel Greenblatt) % | -91.54 | |||||
| ROCE % | -59.57 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 19.59 | |||||
| PB Ratio | 2.5 | |||||
| EV-to-EBIT | -24.56 | |||||
| EV-to-EBITDA | -88.86 | |||||
| EV-to-Revenue | 216.7 | |||||
| EV-to-FCF | -41.93 | |||||
| Earnings Yield (Greenblatt) % | -4.07 | |||||
| FCF Yield % | -2.59 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:TYPTF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Tryptamine Therapeutics Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.171 | ||
| EPS (TTM) ($) | -0.025 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 54.21 | ||
| 14-Day ATR ($) | 0.010889 | ||
| 20-Day SMA ($) | 0.021195 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 0.0007 - 0.0385 | ||
| Shares Outstanding (Mil) | 1,276.42 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Tryptamine Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Tryptamine Therapeutics Ltd Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Tryptamine Therapeutics Ltd Frequently Asked Questions
What is Tryptamine Therapeutics Ltd(TYPTF)'s stock price today?
The current price of TYPTF is $0.03. The 52 week high of TYPTF is $0.04 and 52 week low is $0.00.
When is next earnings date of Tryptamine Therapeutics Ltd(TYPTF)?
The next earnings date of Tryptamine Therapeutics Ltd(TYPTF) is .
Does Tryptamine Therapeutics Ltd(TYPTF) pay dividends? If so, how much?
Tryptamine Therapeutics Ltd(TYPTF) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers